NCT02729298: First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have tumors that have progressed after achieving a best documented response of at least stable disease (i.e.. pathologic or complete response) following at least 2 cycles (8 weeks) of immunotherapy
Exclusions: Patients with untreated symptomatic brain metastasis that requires local therapy- see trial for details

Comments are closed.

Up ↑